Section of Anaesthesia and Intensive Care Medicine, Department of Physiology and Pharmacology, Karolinska Institutet, SE-171 77 Stockholm, Sweden.
Clin Chim Acta. 2012 Oct 9;413(19-20):1661-7. doi: 10.1016/j.cca.2012.05.010. Epub 2012 May 18.
The distinction between monomeric human neutrophil lipocalin/neutrophil gelatinase-associated lipocalin (HNL/NGAL), secreted by injured kidney tubular cells, and dimeric HNL/NGAL, released by activated neutrophils, is important to accurately diagnose acute kidney injury (AKI).
132 urine samples from 44 intensive care unit (ICU) patients and five urine samples from non-ICU patients with urinary tract infections (UTIs) were analyzed by two monoclonal enzyme-linked immunosorbent assays (ELISA-1 and ELISA-2). The presence of monomeric and/or dimeric HNL/NGAL in each sample was visualized by Western blotting.
The ELISA-1 detected both monomeric and dimeric HNL/NGAL whereas the ELISA-2 almost exclusively detected dimeric HNL/NGAL with an area under the receiver-operating characteristics curve (AuROC) of 0.90. The ELISA-1/ELISA-2 ratio detected the monomeric form with an AuROC of 0.92. In 32 AKI patients, dimer-specific ELISA-2 levels decreased pre-AKI whereas the monomer-specific ELISA-1/ELISA-2 ratio gradually increased beyond AKI diagnosis. High ELISA-2 levels and/or low ELISA-1/ELISA-2 ratios detected a predominance of dimeric HNL/NGAL in urine from the patients with UTIs.
In combination, our two ELISAs distinguish monomeric HNL/NGAL, produced by the kidney epithelium, from dimeric HNL/NGAL, released by neutrophils during AKI development, as well as reduce the confounding effect of neutrophil involvement when bacteriuria is present.
单体人中性粒细胞明胶酶相关脂质运载蛋白/中性粒细胞明胶酶相关脂质运载蛋白(HNL/NGAL)与损伤的肾小管细胞分泌有关,二聚体 HNL/NGAL 与激活的中性粒细胞释放有关,区分这两者对于准确诊断急性肾损伤(AKI)非常重要。
分析了来自 44 名重症监护病房(ICU)患者的 132 份尿液样本和 5 份来自非 ICU 尿路感染(UTI)患者的尿液样本,使用两种单克隆酶联免疫吸附试验(ELISA-1 和 ELISA-2)进行分析。通过 Western blot 可视化每个样本中单体和/或二聚体 HNL/NGAL 的存在。
ELISA-1 检测到单体和二聚体 HNL/NGAL,而 ELISA-2 几乎只检测到二聚体 HNL/NGAL,其受试者工作特征曲线(ROC)下面积(AuROC)为 0.90。ELISA-1/ELISA-2 比值检测单体形式,其 AuROC 为 0.92。在 32 名 AKI 患者中,二聚体特异性 ELISA-2 水平在 AKI 前降低,而单体特异性 ELISA-1/ELISA-2 比值在 AKI 诊断后逐渐升高。高 ELISA-2 水平和/或低 ELISA-1/ELISA-2 比值检测到患者尿液中二聚体 HNL/NGAL 占主导地位。
我们的两种 ELISA 结合使用,可以区分由肾脏上皮细胞产生的单体 HNL/NGAL 和在 AKI 发展过程中由中性粒细胞释放的二聚体 HNL/NGAL,同时减少了当存在菌尿时中性粒细胞参与的混杂影响。